Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis ...

In the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF), finerenone reduced the risk of the primary end point similarly in women and ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Finerenone (Kerendia) yielded minimal renal benefit in patients with heart failure with mildly reduced or ...

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, resulted in more frequent hyperkalemia and less ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid ...

Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, and ACEi or ARB), which might lead to better kidney outcomes in this ...

SAN DIEGO -- Finerenone (Kerendia) yielded minimal renal benefit in patients with heart failure with mildly reduced or ...

SAN DIEGO — In patients with heart failure, treatment with finerenone provides some benefits in reducing the risk for macroalbuminuria. However, no significant changes are observed in estimated ...

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...